Drug Approval | July 09, 2024
Olverembatinib approved for commercialization in Macau China
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Ibara will drive AI-powered clinical research innovation
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
This strategic decision will unlock significant value for our scientific and industrial products business
Subscribe To Our Newsletter & Stay Updated
